Physicochemical-viral synergism during Epstein-Barr virus infection: a review. 1988

E E Henderson
Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA 19140.

Infection with the Epstein-Barr virus (EBV), a ubiquitous herpesvirus, may be asymptomatic or may result in any one of a number of mild to severe hematopoietic disorders. Besides causing infectious mononucleosis, EBV has been associated with 95% of endemic African Burkitt's lymphoma and 10%-20% of the sporadic form of Burkitt's lymphoma outside Africa. EBV has also now been associated with all histological forms of nasopharyngeal carcinoma. During the acute phase of infectious mononucleosis, a surprisingly large number of EBV-infected cells can be detected in the peripheral circulation (up to 0.05%). EBV also replicates in epithelial cells in the oropharyngeal region. It is known that physicochemical carcinogens can act synergistically with tumor viruses to enhance both viral replication and cellular transformation. Several laboratories have shown that chemical carcinogens and, in particular, DNA-alkylating agents can enhance EBV replication, EBV-induced lymphocyte transformation, and EBV-associated malignant conversion. Since there are approximately 10(12) lymphocytes in an adult, the large number of EBV-infected cells present in the circulation and oropharynx during infection would present an extraordinarily large target for carcinogen interaction. Moreover, after infection, EBV remains latent in lymphoid cells for life. When these findings are considered in light of analytical and descriptive epidemiological evidence suggesting that, in addition to EBV infection, other environmental cofactors are important in EBV-associated tumor formation, the question could be asked whether these cofactors are physicochemical carcinogens. In an attempt to answer this question, I will review the ways in which physicochemical carcinogens can influence viral replication and virally induced transformation; aspects of the biology of the EBV-lymphocyte-epithelial cell interaction that make this system perhaps unique in terms of possible physicochemical interactions; the epidemiological and experimental evidence supporting EBV-physicochemical carcinogen synergisms; and finally, possible mechanisms whereby chemicals could influence the outcome of EBV infection and the probability of these events occurring during naturally acquired EBV infection.

UI MeSH Term Description Entries
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D002472 Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus. Transformation, Viral Cell,Viral Cell Transformation,Cell Transformations, Viral,Transformations, Viral Cell,Viral Cell Transformations
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications

Related Publications

E E Henderson
January 2014, Frontiers in microbiology,
E E Henderson
January 1990, American journal of otolaryngology,
E E Henderson
February 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
E E Henderson
February 1994, Pediatrics in review,
E E Henderson
August 2000, The New England journal of medicine,
E E Henderson
September 2010, Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,
E E Henderson
July 1997, The Journal of infectious diseases,
E E Henderson
March 1989, The Journal of infection,
E E Henderson
December 1987, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!